A Danish-American biotech company reports that its experimental Alzheimer’s drug MNA-001 was well tolerated in a Phase 1 study and shifted markers of immune ageing in the spinal fluid of elderly volunteers toward the levels seen in younger people. Whether that helps memory or thinking is still unknown.
Researchers gave a pill to elderly volunteers and then examined the fluid surrounding their brains and spinal cords. Some of the markers they found there had moved toward the levels of younger, healthy people. Muna Therapeutics, based in Copenhagen and Boston, announced the Phase 1 results of its drug MNA-001, and the findings were reported by Longevity.Technology on 3 November.
The target: a receptor on the brain’s maintenance cells
MNA-001 is an oral small-molecule drug that acts on TREM2, a protein found on microglia, the brain’s resident maintenance cells. Microglia respond to damage, clear cellular debris and misfolded proteins, and regulate inflammation. Genetic variants that reduce TREM2 activity raise the risk of Alzheimer’s disease, which is a main reason the protein has drawn so much interest.
According to the company, MNA-001 helps keep TREM2 in a signalling-ready state at the cell surface so the pathway stays active. Chief scientific officer Niels Plath says the goal is both to activate microglia and to restore an appropriate response to disease pathology.
What the trial found
The study was randomised, double-blind and placebo-controlled, with single and multiple rising doses in younger volunteers and an additional group of elderly participants. The company reports no serious adverse events, no dropouts because of side effects, and mostly mild side effects. Blood levels of the drug rose in proportion to the dose and were similar in younger and elderly people, which supports once-daily dosing. The drug also reached the central nervous system.
As a marker that the drug was hitting its target, soluble TREM2 fell in both spinal fluid and plasma as doses rose, then levelled off at well-tolerated exposures, which suggests going higher would add little. The finding the company highlights most comes from exploratory analyses of spinal fluid: after repeated dosing in elderly participants, markers linked to age, to microglial and innate immune activity and to neuronal stress moved toward the levels seen in younger participants.
How much weight the results can bear
The article is careful here, and so should readers be. The shifts are exploratory, meaning they were not the primary question the study was designed to answer. The company’s release gives no participant numbers. A change in a laboratory marker does not mean anyone’s memory or thinking improved, as the company itself says. Chief executive Michel Detheux describes the drug as having “best-in-class” potential, which the article rightly treats as a forecast, not a finding. His own next milestone is to show whether this biological activity translates into a benefit for patients.
What comes next
Muna expects to begin a Phase 2 study in early 2027, comparing MNA-001 with placebo. It will use cognitive assessments and biomarkers of disease progression, along with exploratory fluid, imaging and functional markers, to see how the drug affects people and to look for predictors of who responds. The company also says the drug might be used on its own or alongside other Alzheimer’s therapies. The article’s author notes that the study looked at ageing biology and not only at disease, which makes the early signal interesting, but that Phase 2 results are needed to know whether it matters for anyone’s brain health.
Why the region should care
Muna is a European company, and Alzheimer’s disease is a growing burden in the region’s ageing societies. The article does not say where the Phase 2 study will recruit, so it is not yet clear whether Central and Eastern European centres will take part. Any wider access would depend on that trial’s results and on European regulatory approval, which is unlikely before the end of the decade at the earliest. The practical connection to other recent work is the question of whom to treat: large blood-marker studies such as UKB-PRISM aim to identify people at risk years before symptoms, and drugs aimed at microglia would need such tools to find the right patients early.
Disclaimer. This article is for general information and is not investment, financial, legal or tax advice, nor a recommendation to buy, sell or hold any security. Muna Therapeutics is a clinical-stage company, and investments in early-stage biotechnology carry a high risk of loss: most drug candidates fail, and Phase 1 results do not predict whether a drug will work in patients or be approved. Statements by company executives about potential, timelines and plans are forward-looking and may not come true. Readers should do their own research and consult a suitably authorised financial adviser before making any investment decision. Nothing here is medical advice; consult a doctor about any health concern.
Transparency Note: This article was prepared with the assistance of artificial intelligence technologies. Every piece is thoroughly reviewed and verified by our editorial team, who retain full responsibility for the final content.
Picture: Freepik